This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

University Hospitals Receives $14.5 Million In New Gifts

This is Mrs. Coleman's third major investment in UH's cancer clinical trials program. In 2001, she made a $1.5 million endowed gift to establish the Dr. Lester E. Coleman, Jr. Chair in Cancer Research and Therapeutics. Mrs. Coleman further honored her husband's legacy in 2007 by making an additional $1.5 million gift to complete a vital capital project: the Kathleen A. and Dr. Lester E. Coleman Clinical Research Suite at Seidman Cancer Center, a leading-edge clinical trials patient unit featuring inpatient beds for clinical trials, along with a control room for cell processing and diagnostics. Through her advocacy and personal support, as part of the Discover the Difference Campaign, Mrs. Coleman is currently leading a $15 million campaign aimed at advancing cancer clinical trials.

"The Colemans have done so much to advance cancer care, from Les' participation in a clinical trial to Kathy's generosity and volunteer leadership at Seidman Cancer Center," said Nathan Levitan, MD, President, UH Seidman Cancer Center. "This new gift will enable us to build upon our long legacy of being at the forefront of cancer research and will have a tremendous impact on achieving our goal: Curing Cancer Every Day."

As one of the nation's leaders in clinical research, Seidman Cancer Center is dedicated to innovative treatments and clinical research through more than 300 ongoing studies aimed at cancer treatment and prevention. As part of the Case Comprehensive Cancer Center at Case Western Reserve University, Seidman Cancer Center is also one of only seven centers in the nation with National Cancer Institute (NCI)-designated Phase I and Phase II trials with new drugs.

"Les and I were so grateful for the care he received at Seidman Cancer Center and he enjoyed a greater quality of life through participating in the clinical trials program," said Mrs. Coleman. "This gift honors his lifelong commitment to advancing science and I am so excited to support the advancement of clinical trials which will have a profound impact on patients today and for generations to come."

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs